Triveram in patients with hypertension and concomitant primary hypercholesterolemia or mixed hyperlipidemia

TRIVERAM-PRACTICE: an open, multi-center, single-arm, non-interventional, observational study in hypertensive outpatients with concomitant primary hypercholesterolemia or mixed hyperlipidemia treated with Triveram in Germany

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN54275632

Enrollment

1350

Registered

2016-06-30

Start date

2016-04-04

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension with concomitant primary hypercholesterolemia or mixed hyperlipidemia Circulatory System

Interventions

This is strictly a non-interventional observational study. Only interventions in line with and not exceeding the standard medical routine are allowed. All patients involved in the study will be treate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients with essential hypertension and concomitant hypercholesterolemia or mixed hyperlipidemia eligible for the treatment with Triveram® in line with the marketing authorization for whom the treatment decision was done prior to study inclusion.

Exclusion criteria

Exclusion criteria: N/A

Design outcomes

Primary

Measure	Time frame
Office blood pressure and lipid parameters measured within the daily medical routine at inclusion, after approx. 1 month and at study final examination after approx. 4 months.	—

Secondary

Measure	Time frame
1. Ambulatory blood pressure monitoring only in measured as part of the medical routine at inclusion, after approx. 1 month and at study final examination after approx. 4 months 2. Home blood pressure at inclusion, after approx. 1 month and at study final examination after approx. 4 months 3. Assessment of therapy adherence measured by means of the Hill-Bone-Scale at inclusion and at study final examination after approx. 4 months 4. Assessment of pill burden and therapy satisfaction at inclusion and at study final examination after approx. 4 months	—

Measure

Time frame

1. Ambulatory blood pressure monitoring only in measured as part of the medical routine at inclusion, after approx. 1 month and at study final examination after approx. 4 months 2. Home blood pressure at inclusion, after approx. 1 month and at study final examination after approx. 4 months 3. Assessment of therapy adherence measured by means of the Hill-Bone-Scale at inclusion and at study final examination after approx. 4 months 4. Assessment of pill burden and therapy satisfaction at inclusion and at study final examination after approx. 4 months

—

Countries

Germany

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026